Wuling Zhu

Dr. Wuling Zhu


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2020 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
ZNZhiyuan Niu
Zhiyuan Niu
GCGuanxu Chen
Guanxu Chen
WCWei Chang
Wei Chang
PSPengyang Sun
Pengyang Sun
ZLZhixia Luo
Zhixia Luo
WZWuling Zhu
Wuling Zhu

1 June 2020 in Molecular Immunology
Verified
Journal Article
Closed access
CLChengui Lu
Chengui Lu
CGChangjiang Guo
Changjiang Guo
HCHan Chen
Han Chen
HZHuiyong Zhang
Huiyong Zhang
LZLingtong Zhi
Lingtong Zhi
WZWuling Zhu
Wuling Zhu

1 October 2019 in Molecular Immunology
Verified
Journal Article
Closed access
CGChangjiang Guo
Changjiang Guo
XWXiaoyin Wang
Xiaoyin Wang
HZHuiyong Zhang
Huiyong Zhang
LZLingtong Zhi
Lingtong Zhi
TLTanyu Lv
Tanyu Lv
WZWuling Zhu
Wuling Zhu

25 February 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
LZLingtong Zhi
Lingtong Zhi
ZZZikang Zhang
Zikang Zhang
QGQing Gao
Qing Gao
CSChongye Shang
Chongye Shang
WHWenhui He
Wenhui He
WZWuling Zhu
Wuling Zhu
Chimeric antigen receptor (CAR) engineered natural killer (NK) cells have shown their efficacy and superiority against cancer and possess the potential to become off-the-shelf immunotherapy products. Nonetheless, some challenges associated with CAR-NK cells still exist including inhibitory receptor engagement, antigen escape, and inadequate activation. Given this, based on the concept of synthetic biology, we rationally designed a novel dual-targeted CAR (dtCAR), primarily comprising PD-L1 nanoantibody (PD-L1Nb) and NKG2D as the ectodomain, transmembrane and cytoplasmic domains (CP) of CD28, and the CP of 4-1BB and CD3ζ. NK92 cells were engineered to express this third-generation of dtCAR. We then elucidated the role of dtCAR-modified NK92 cells against cancer cells in vitro and in vivo. In vitro, the dtCAR-NK92 cells could still retain the characteristics of parental NK cells and exhibit improved NK cell cytotoxicity and produce more cytokines than NK92 cells when they were co-cultured with human lung cancer H1299 cells. Notably, the dtCAR-NK92 cell therapy might elicit clearance of H1299 cells by pyroptosis. Additionally, dtCAR-NK92 cells could considerably inhibit tumor growth in the human lung cancer H1299 cell tumor model. We confirmed that expression of dtCAR enhanced NK92-cell activation and killing in vitro and in vivo, which provides a novel immunotherapeutic strategy for using NK-tailored CAR-engineered NK92 cells to treat human lung cancer.

1 March 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MLMingfeng Li
Mingfeng Li
LZLingtong Zhi
Lingtong Zhi
MYMeichen Yin
Meichen Yin
CGChangjiang Guo
Changjiang Guo
HZHuiyong Zhang
Huiyong Zhang
WZWuling Zhu
Wuling Zhu

1 February 2023 in Molecular Immunology
Verified
Journal Article
Closed access
CGChangjiang Guo
Changjiang Guo
HCHan Chen
Han Chen
JYJie Yu
Jie Yu
HLHui Lu
Hui Lu
QXQing Xia
Qing Xia
WZWuling Zhu
Wuling Zhu